Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 20;27(16):3145-54.
doi: 10.1002/sim.3123.

Proper inference from Simon's two-stage designs

Affiliations

Proper inference from Simon's two-stage designs

Tatsuki Koyama et al. Stat Med. .

Abstract

Simon's two-stage designs are very popular for phase II clinical trials. A literature review revealed that the inference procedures used with Simon's designs almost always ignore the actual sampling plan used. Reported P-values, point estimates and confidence intervals for the response rate are not usually adjusted for the design's adaptiveness. In addition, we found that the actual sample size for the second stage is often different from that planned. We present here a method for inferences using both the planned and the actual sample sizes. The conventional and the preferred inference procedures usually yield similar P-values and confidence intervals for the response rate. The conventional inference, however, may contradict the result of the corresponding hypothesis testing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Extension of the observed conditional P value to other x1 values based on π*. The solid line is the conditional type I error rate, and the dotted line is the conditional power under the alternative. The conditional P value is indicated by a solid circle. The bold line is the conditional power function that goes through this point.

References

    1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 1989;10(1):1–10. - PubMed
    1. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995;51(4):1372–1383. - PubMed
    1. Conaway MR, Petroni GR. Design for phase II trials allowing for a trade-off between response and toxicity. Biometrics. 1996;52(4):1375–1386. - PubMed
    1. Thall PF, Cheng SC. Optimal two-stage designs for clinical trials based on safety and efficacy. Statistics in Medicine. 2001;20(7):1023–1032. - PubMed
    1. Panageas KS, Smith A, Gönen M, Chapman PB. An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials. 2002;23(4):367–37. - PubMed

Publication types

LinkOut - more resources